While further research is needed to confirm these effects, the current literature supports the potential utility of GLP-1RAs in IIH management
Since 2019, there has been a 1,500% spike in poison center reports involving GLP-1 medications like Ozempic, with 1,678 cases already reported in 2025
Potential benefits of combining intermittent fasting and GLP-1 medications Pairing intermittent fasting with GLP-1 medications may offer several synergistic benefits: Enhanced weight loss: Both approaches reduce appetite and calorie intake, potentially leading to faster and more sustainable weight loss
Severe insulin resistance associated with conditions like non-alcoholic fatty liver disease (NAFLD) or metabolic syndrome may require higher semaglutide doses or combination therapy to overcome
Supplementary information Legends of Supplementary Tables 112
Trim and Fill imputed three missing studies, shifting the effect size downward and highlighting a likely overestimation of treatment effects due to bias